Peter Anevski bought $1.9M of Progyny (PGNY)
Executed Nov 13 2025, disclosed Nov 17 2025, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Nov 17 2025), the stock returned +2.0% (delay-adjusted); from the execution session (Nov 13 2025), +12.2%. Derived: entry at the session's open, exit at the close 20 sessions later.
Peter Anevski (CHIEF EXECUTIVE OFFICER) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Progyny, Inc. (PGNY). Across 1 priced purchase filing, the average 21-session return was +12.2% from execution and +2.0% from disclosure (delay-adjusted; derived). The largest single filing was $1.9M of PGNY (79,500 sh × $24.29, as filed), executed Nov 13 2025.
Healthcare · Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United Stat…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→209,500 sh × $14.48
Exec Dec 23 2024
Filed Dec 26 2024 · 5:30 PM ET